Indaptus Therapeutics (NASDAQ:INDP) Sees Large Volume Increase – Here’s What Happened

Shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) saw strong trading volume on Thursday . 25,631,092 shares traded hands during trading, an increase of 10,529% from the previous session’s volume of 241,142 shares.The stock last traded at $4.8910 and had previously closed at $2.21.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Indaptus Therapeutics Stock Up 111.0%

The stock has a market capitalization of $528.15 million, a PE ratio of -0.32 and a beta of 1.25. The stock’s 50 day moving average price is $2.07 and its 200-day moving average price is $2.18.

Indaptus Therapeutics (NASDAQ:INDP) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($1.87) by $1.64.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC bought a new stake in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 7.06% of the company’s stock.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.